Genentech Hemophilia Therapy Gets Solid Endorsement From ICER

Hemlibra could save health care system $1.85m per patient annually as it displaces current approaches to treatment, Institute for Clinical and Economic Review projects in draft report.

Genentech Inc.'s recently-approved therapy to prevent bleeding in a small subgroup of hemophilia patients, Hemlibra (emicizumab-kxwh), offers significantly improved efficacy and savings to the health care system compared to existing treatments, the Institute for Clinical and Economic Review concludes in a draft report.

"The findings of our analysis suggest that emicizumab prophylaxis provides gains in quality-adjusted life years at substantially lower costs over...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Health Technology Assessment

More from Market Access